Navigation Links
Omeros Licenses Novel Antifibrinolytic Agents
Date:1/5/2011

logical side effects. Worldwide revenues for Trasylol® (aprotinin), which was permanently withdrawn in 2008 after its use was found to be associated with increased mortality, peaked at $285 million in 2005.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release and include Omeros' ability to advance an antifibrinolytic agent rapidly into the clinic and the ability of its agents to provide more effective bleeding control with fewer side effects than other antifibrinolytics. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
2. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
3. Omeros to Present at the BioCentury NewsMakers Conference
4. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
5. Omeros Successfully Unlocks Orphan GPCRs
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
11. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015  Profil Institute for ... on diabetes and obesity, announced today a new textbook,  ... Development,  published by Springer, a leading global scientific publisher. ... analyze and illustrate techniques for use in early phase ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition ... & by End User - Global Forecast to 2019" ... diagnostics market is valued at $1,228.58 million in 2014 and ... reach $2,230.72 million by 2019. Allergy diagnostics is used to ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Oct. 15 /PRNewswire-FirstCall/,-- Lexicon Pharmaceuticals, Inc. (Nasdaq: ... clinical trial results for LX1031 at the ... in Philadelphia, Pennsylvania. The,studies demonstrated that LX1031 ... that exposure levels in blood were low. ...
... control in patients with type ... has been accepted for publication, OWINGS MILLS, Md., Oct. ... a study conducted by researchers at the,Johns Hopkins University Bloomberg ... peer-reviewed journal which is scheduled for,release in an early 2008 ...
Cached Medicine Technology:Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome 2Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome 3Medifast, Inc. Announces Acceptance for Publication of Clinical Efficacy Study 2
(Date:1/22/2015)... City, Florida (PRWEB) January 22, 2015 IsoComforter, ... cold therapy machine with patented IsoTube design to treat specific ... has introduced the most progressive and easy to use patented ... treat post-operative and sports related orthopedic and muscle injuries. ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting a ... insurance policy . , Some types of vehicles cannot be ... newly released blog post to see if their vehicle qualifies for ... are some of the cars that cannot be covered by a ...
(Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
Breaking Medicine News(10 mins):Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... challenges in managing their blood glucose levels, and it ... system providing continuous real-time glucose readings. Today, The Endocrine ... on settings where patients are most likely to benefit ... way to self-check blood glucose levels is to prick ...
... caught in its early stages, prostate cancer is treatable ... threshold, the disease becomes largely resistant to current treatments. ... of cancer biologists $9.55 million over five years to ... progresses to the therapy-resistant state. The Program Project ...
... Netherlands, 11 October 2011 Alzheimer,s disease (AD) is ... the world. A new supplement to the ... clearly shows that multiple imaging systems are now available ... "Alzheimer,s disease is now seen as a ...
... published in the October issue of the Journal of ... breast malignancies accounting for 0.5 to one percent of all ... patients. Population-based estimates indicate that the incidence of malignant phyllodes ... frequencies in Hispanic women. Previous studies have focused on ...
... the start of 2011, the active ingredient ticagrelor can ... (ASA) to avoid blood clots in patients with acute ... Quality and Efficiency in Health Care (IQWiG) has now ... coronary syndrome (ACS) in comparison with conventional drugs. This ...
... team of researchers, Gloria Petersen, Ph.D. , of ... California, San Francisco, and Susan Wolf, J.D., of the University ... the National Cancer Institute and the National Human Genome Research ... genetic research results, such as DNA test results, from tissue ...
Cached Medicine News:Health News:Experts find continuous glucose monitoring beneficial in maintaining target blood glucose levels 2Health News:$9.55 million NCI grant targets the resistance of advanced prostate cancer 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 2Health News:Advances in brain imaging can expedite research and diagnosis in Alzheimer's disease 3Health News:Hispanic women have higher incidence of rare breast tumor 2Health News:Ticagrelor: Considerable added benefit for specific patients 2Health News:Ticagrelor: Considerable added benefit for specific patients 3Health News:Ticagrelor: Considerable added benefit for specific patients 4